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Aluminium phosphide (AlP) is a highly toxic pesticide that inhibits cytochrome oxidase c and causes 
oxidative stress. Death results from refractory cardiogenic shock due to myocardial dysfunction. 
There is very little information regarding extracorporeal life support in severe AlP poisoning. Although 
several therapies are available, none are curative. We report on the use of an intra-aortic balloon pump 
(IABP) in a 24-year-old woman brought to our hospital after an intentional ingestion of a tablet of 
AlP (3 g), which caused refractory AlP-induced cardiogenic shock and acute respiratory distress 
syndrome (ARDS). The patient underwent gastric lavage with potassium permanganate, received 
sodium bicarbonate intravenously, and was admitted to the intensive care unit. Echocardiography at 
36 h post ingestion showed a left ventricular ejection fraction (LVEF) of <20 %. An IABP was inserted 
and the patient’s vital signs stabilised. After eight days, the IABP was removed and on day 20, the 
patient’s LVEF increased to 50 %. IABP was successfully used and may improve future prognoses 
for severely poisoned AlP patients with refractory cardiogenic shock. We encourage clinical 
toxicologists to examine this new treatment. 
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Aluminium phosphide (AlP) is an extremely 
efficient substance used as both an outdoor and indoor 
pesticide (1-5). It is easily available in Asian countries 
such as India and Iran, where it is also known as “rice 
tablet” because of its frequent use in the protection of 
stored rice and grains from rodents and other 
household pests (6). Many cases of suicide attempts 
have been reported with rice tablets in these countries 
(3, 5). In fact, AlP is generally the most commonly 
used fatal intentional poison in Iran and India (3, 7, 
8). AlP poisoning leads to multiorgan failure (9, 10), 
but death following this poisoning is most often caused 
by refractory hypotension and cardiogenic shock in 
the form of toxic chemical myocarditis, which leads 
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to severe left ventricular dysfunction (8, 11, 12). The 
exact mechanism of its toxicity is unclear, but the 
release of phosphine gas as well as cytochrome 
oxidase inhibition, oxidative stress, and free oxygen 
radicals have been suggested as the main causes of 
toxicity (8, 13). Unfortunately, there is no specific 
antidote and all treatments, such as gastric lavage with 
potassium permanganate, administration of coconut 
oil (14), etc., are only supportive procedures. 
Refractory hypotension is generally managed by early 
resuscitation with fluid and vasoactive agents 
(norepinephrine or phenylephrine, dopamine, and 
dobutamine). Moreover, Vitamins C and E (3), 
hyperbaric oxygenation (15), N-acetyl cysteine (16), 
digoxin (11), and recently intra-aortic balloon pump 
(IABP) (12) have been used to treat toxic myocarditis 
due to rice tablet poisoning. 
AlP is highly reactive and any contact with 
moisture will result in decomposition to phosphine 
gas. Phosphine poisoning has a mortality rate as high 
as 70-100 % (9, 10, 17). Its main mechanism of 
toxicity is the inhibition of cytochrome oxidase c and 
oxidative stress (8, 13, 18). As a result, AlP poisoning 
can cause refractory cardiogenic shock and metabolic 
acidosis (8). Currently, there is no specific antidote 
for AlP poisoning and treatment is only supportive. 
This paper reports a successful treatment of AlP-
induced cardiogenic shock using an IABP in a 24-year-
old woman.
Case report
The Imam Reza hospital in Mashhad, Iran is the 
referral hospital for poisoned patients in Eastern Iran 
and one of the largest toxicology hospitals in the world 
(19, 20). A 24-year-old woman who had intentionally 
ingested one three-gram tablet of aluminium 
phosphide (AlP) was referred to our hospital and 
admitted to the Toxicology Emergency Department. 
She ingested the tablet with four glasses of water, 
vomited immediately, and was presented fully 
conscious to a local hospital complaining of weakness, 
cold extremities, and thirst. The patient’s initial vital 
signs were as follows: blood pressure 90/50 mm Hg; 
pulse rate 120 bpm; respiratory rate 20 per minute; 
and body temperature 37.1 °C, with an oxygen 
saturation of 96 % at room air. Initial blood gas 
analysis showed a pH of 7.39; PCO2 21.2 mm Hg; 
PaO2 59 mm Hg; HCO3 12.9 mmol L
-1; and a base 
excess (BE) of -9.1 mmol L-1. The patient underwent 
gastric lavage with potassium permanganate (1/10000) 
and was given intravenous sodium bicarbonate 
(NaHCO3) 44 mEq every 15 min. The patient was then 
admitted to our Centre (about three hours post-
ingestion of AlP). Vital signs on arrival were: blood 
pressure 100/70 mm Hg; pulse 130 bpm; respiratory 
rate 18 per minute; and body temperature 37 °C with 
an oxygen saturation of 96 %. Electrocardiography 
(ECG) revealed sinus tachycardia with no ST-T 
changes, but serial ECGs showed non-specific ST and 
T-wave changes and interventricular conduction delay 
(Figure 1). Serial vital signs and laboratory data are 
shown in Table 1. The patient was admitted to the 
intensive care unit (ICU) and received intravenous 
crystalloid fluid (normal saline; 150 mL h-1 until her 
thirst was resolved), vasopressors (dopamine; 
10 µg kg-1 min-1, and norepinephrine; 4 µg min-1), 
digoxin 0.5 mg stat followed by 0.25 mg q6h for 24 h 
and 0.25 mg daily, afterwards, glucagon 4 mg h-1, 
magnesium sulphate 2 g stat followed by 1 g q6h, 
sodium bicarbonate (until correction of metabolic 
acidosis), vitamin C 500 mg  per day, vitamin E 100 IU 
per day, heparin 5000 IU BID and N-acetylsycteine 
300 mg kg-1 through 24 h in three divided doses. About 
24 h later, the patient experienced tachypnea 
(respiratory rate 45 per minute) and her O2 saturation 
dropped to 70 %. 
The patient also complained of retrosternal 
discomfort and was therefore intubated and placed on 
mechanical ventilation with the following parameters: 
synchronised intermittent mandatory ventilation 
(SIMV) mode of fractional inspired oxygen (FiO2) 
was 50 %, tidal volume was 350 mL, and positive 
end-expiratory pressure (PEEP) was 7 mm H2O. 
However, her O2 saturation remained at 88-92 % and 
gasometry showed an arterial oxygen pressure (PaO2)
level of 50 mm Hg. A chest X-ray confirmed acute 
respiratory distress syndrome (ARDS) (Figure 2). 
ARDS was defined as diminished PaO2 to FiO2 ratio 
(P to F ratio smaller than 200). Thirty-six hours after 
admission, bedside echocardiography showed a left 
ventricular ejection fraction (LVEF) of less than 20 %, 
global hypokinesia of the left ventricle and mitral 
valve regurgitation (MR) and an IABP was inserted 
by a cardiac surgeon. The patient had no 
contraindications to the use of an IABP (e.g., sepsis, 
aortic aneurysms, peripheral vascular diseases, 
neurological deficits, aortic dissection, etc.). 
On the third day of ICU admission, ventilator 
acquired pneumonia (VAP) occurred and the patient’s 
temperature increased to 38.5 °C. Meropenem (1 g 
three times per day), amikacin (500 mg BID), and 
vancomycin (1 g BID) were administered. On day 
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Table 1 Clinical and paraclinical findings of our case of AlP poisoning
laboratory tests / time after 
ingestion
on 
admission 12 h 24 h day 5 day 8 day 10 day 18 day 26
Blood pressure (mm Hg) 100/70 90/60 80/50 105/65 110/70 105/80 120/70 115/80
Pulse rate (bpm) 130 160 150 110 86 90 103 98
Respiratory rate (pm) 20 30 45 SIMV SIMV SIMV 20 15
O2 saturation (%) 94 86 70 91 100 100 96 95
pH 7.48 7.30 6.90 7.47 7.49 7.38 - 7.42
PaCO2 (mm Hg) 17.6 19.9 69 45 34.8 43.9 - 32.3
PaO2 (mmHg) 58 52 50 56 60 62 65 65
Serum HCO3 (mmol L
-1) 13.1 10 15.4 32.9 28.2 26.5 - 21.4
WBC (103 µL) 16.5 - 23 - 23 22.6 14.1 4.4
Hb (g dL-1) 13.7 - 14.4 - 8.4 8.7 9 10
Platelet count (103 µL) 232 - 194 - 81 131 267 316
Na (meq L-1) 140 - 139 144 139 136 138 140
K (meq L-1) 4 - 3.9 2.6 4.6 4.4 4.1 3.8
Prothrombin time (s) 12.5 - - - 15.6 14.4 - 13.3
Creatinine (mg dL-1) 0.6 - - 0.8 0.8 0.7 0.6 0.9
Glucose (mg dL-1) 145 - 485 45 169 155 135 109
Creatine phosphokinase (IU L-1) 219 - - - 648 203 - 124
AST* (IU L-1) 52 - - - 72 43 45
ALT** (IU L-1) 75 - - - 273 216 89
SIMV - synchronised intermittent mandatory ventilation
*Aspartate aminotransferase
**Alanine aminotransferase
four, sudden complete cardiac arrest occurred; 
however, fortunately, the patient responded to 
resuscitation. After stabilization of vital signs, the 
IABP was removed (8 days after insertion). Repeated 
echocardiography on day 20 of admission showed an 
LVEF of 50 %.
Surprisingly, our patient exhibited thrombocytopenia, 
hypokalaemia, and variations in haemoglobin between 
the second and the eighth day of admission (Table 1), 
maybe due to receiving heparin. The administered 
antibiotics were the other possible causes of acute 
thrombocytopenia (21, 22). Hypokalaemia in our 
patient was probably due to the administration of 
sodium bicarbonate to correct acidosis, although there 
is evidence that AlP can affect potassium levels in 
cases of poisoning (9, 23). Variations in haemoglobin 
were probably due to haemolysis induced by the IABP 
as an external device. Mean corpuscular volume 
amounts have been reported to be at maximum levels 
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Figure 1 Electrocardiography of AlP poisoned case. Electrocardiography (ECG) revealed sinus tachycardia with no ST-T 
changes; but serial ECGs showed non-specific ST and T-wave changes and interventricular conduction delay
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due to the release of unmaturated red blood cells into 
circulation from bone marrow hyperactivity (24).
The patient’s medication (vasopressors, calcium 
gluconate, magnesium sulphate, hydrocortisone, 
vitamin C, and vitamin E) was tapered gradually. After 
consultation with a psychologist, the patient was 
discharged on day 27 in good condition and normal 
vital signs and laboratory tests. A follow-up visit about 
two months later revealed that the patient was 
asymptomatic with no evidence of ongoing toxicity 
or sequelae. 
DISCUSSION
Cardiogenic shock is defined as systolic blood 
pressure <90 mm Hg or 30 mm Hg below the baseline 
during organ dysfunction (25). It is a kind of shock in 
which the failure of the cardiac ventricle causes 
inadequate circulation. It is defined by tissue 
hypoperfusion and hypotension and is a largely 
irreversible and fatal condition (26). Cardiogenic 
shock is commonly caused by damage to the heart 
muscle such as myocardial infarction, arrhythmias, 
cardiomyopathy, etc. Some cases of drug poisoning, 
such as those by β1 adrenergic receptor antagonists 
(e.g. atenolol, propranolol) and calcium channel 
blockers, also lead to profound hypotension and 
cardiogenic shock; similar to those that occur with 
aluminium phosphide (27-29). Cardiogenic shock 
could also be approached by procedures such as 
administration of positive inotropic agents or glucagon 
(11, 30) and enhancing pumping capabilities, which 
should cause a positive inotropic and chronotropic 
effect by stimulating adenosine monophosphate. 
Pumping can also be improved by using an IABP, 
a left ventricular assist device that enhances the 
perfusion of coronary arteries. During an IABP 
procedure, a balloon is inserted via the femoral artery 
and placed below the left subclavian and above the 
renal arteries (31). It is generally used in patients with 
heart failure waiting for heart transplantation, further 
revascularization, and shock. At the end of a systole, 
pumping the balloon causes an increase in aortic blood 
pressure and increases cardiac output and coronary 
perfusion as well as improves central nervous system 
perfusion. 
There have been several cases of intoxication 
where an IABP was applied (27-29), all of which 
involved refractory cardiogenic shock. Janion et al. 
(32) reported successful treatment of combined 
massive drug intoxication using mechanical ventilation 
and IABP, concluding that combined mechanical and 
pharmacological treatment may even prevent multi-
organ insufficiency.
The use of an IABP for the treatment of AlP was 
first reported by Chacko et al. (33) in 2008, in a 
25-year-old female who suffered from severe toxicity 
after ingesting 10 tablets of AlP. Unfortunately, it was 
unsuccessful. A successful treatment of AlP with an 
IABP was first reported by Siddaiah et al. (12) in 2009, 
in a 22-year old female who, suffering with cardiogenic 
shock due to AlP poisoning, was treated with an IABP 
until the effects of AlP resolved. There are no other 
reports in the literature on IABP in the treatment of 
AlP poisoning and the case presented here was the 
second successful one in this regard. 
Our use of an IABP for treating AlP-induced 
cardiogenic shock yielded success in a patient who 
otherwise appeared to have a very poor prognosis due 
to refractory hypotension and ARDS (34, 35). Given 
our success in the case reported here, it is reasonable 
to question why IABP has not been used more often. 
We assume that this most likely relates to the 
unavailability of a cardiac surgeon in Iranian referral 
toxicological centres and probably other countries 
where AlP poisoning is common. Furthermore, to 
improve outcomes, AlP-poisoned patients need 
extensive ICU care after insertion of an IABP and, 
due to the high rate of poisoned patients in the 
aforementioned countries, the lack of ICU beds is 
another limitation that should be considered. 
IABP has also been used in severe LV dysfunction 
in other toxic myocarditis cases (27-30), as IABP 
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Figure 2 Chest X-ray of AlP poisoned case. Acute respiratory 
distress syndrome (ARDS)
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generally reduces afterload and improves coronary 
artery perfusion. Despite many proposed therapies, 
patients with severe AlP poisoning continue to die of 
cardiogenic shock. We recommend the use of this 
treatment in other cases of refractory cardiogenic 
shock from AlP poisoning and encourage clinical 
toxicologists to report on their experiences.
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Sažetak
Primjena intra-aortne balonske pumpe pri kardiogenom šoku uzrokovanom trovanjem aluminijevim 
fosfidom 
Aluminijev fosfid (AlP) visoko je toksičan pesticid koji inhibira citokrom c oksidazu i uzrokuje oksidacijski 
stres. Smrt nastupa nakon refraktornog kardiogenog šoka uslijed miokardijalne disfunkcije. Vrlo je malo 
literature o izvantjelesnim sredstvima održavanja na životu nakon otrovanja AlP-om. Iako postoji određeni 
broj terapija, nijedna ne vodi do potpunoga izlječenja. Prikazan je slučaj uporabe intra-aortne balonske 
pumpe (IABP) kod 24-godišnje žene otrovane namjernim uzimanjem AlP-a (3 g), što je uzrokovalo 
refraktorni kardiogeni šok i akutni respiratorni distres sindrom (ARDS). Pacijentici je želudac ispran 
kalijevim permanganatom, intravenozno je primila natrijev bikarbonat  te je zbrinuta u jedinici za intenzivnu 
skrb. Ehokardiografija 36 h nakon uzimanja tablete AlP-a pokazala je ejekcijsku frakciju lijevog ventrikula 
(LVEF) od < 20 %. Nakon umetanja IABP-a vitalni su se znakovi su se poboljšali. Pumpa je uklonjena 
nakon osam dana, a dvadesetoga dana LVEF je iznosio 50 %. Naši rezultati pokazuju da bi primjena IABP-a 
mogla poboljšati prognoze pacijenata s refraktornim kardiogenim šokom uslijed teškog otrovanja s AlP-
om. Stoga preporučujemo kliničkim toksikolozima da razmotre ovaj novi tretman.
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